Results 61 to 70 of about 20,100 (304)

Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizimab treatment [PDF]

, 2016
Background: Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS). Guidelines discuss the importance of prompt treatment. We report a post hoc analysis investigating the effect of baseline factors, including patient characteristics and ...
Ardissimo, Gianluigi, Delmas, Yahsou, Haller, Herman, Kincaid, John F, Vande Walle, Johan, Wang, Jimmy   +5 more
core   +2 more sources

Eculizumab versus rituximab in generalised myasthenia gravis

Journal of Neurology Neurosurgery & Psychiatry, 2022
Objective Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, is sparse.
Christopher Nelke, Christina B. Schroeter, Frauke Stascheit, M. Pawlitzki, Liesa Regner-Nelke, Niklas Huntemann, Ercan Arat, Menekşe Öztürk, N. Melzer, P. Mergenthaler, A. Gassa, H. Stetefeld, M. Schroeter, B. Berger, A. Totzeck, T. Hagenacker, S. Schreiber, S. Vielhaber, H. Hartung, A. Meisel, H. Wiendl, S. Meuth, T. Ruck   +22 more
semanticscholar   +1 more source

Use of the complement inhibitor Coversin to treat HSCT-associated TMA [PDF]

, 2017
Finding an inherited complement abnormality in HSCT-associated TMA provides a rationale for the use of a complement inhibitor.Alternative complement inhibitors such as Coversin should be considered in patients who are resistant to ...
Amrolia, P, Chiesa, R, Goodship, THJ, Machin, SJ, Mackie, I, Nishimura, J-I, Nunn, MA, Palm, L, Pinto, F, Pryce, JW, Silva, J, Veys, P, Weston-Davies, WH   +12 more
core   +1 more source

A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients

Journal of Neurology
Introduction Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients.
Chiara Pane, Vincenzo Di Stefano, N. Cuomo, A. Sarnataro, C. Vinciguerra, L. Bevilacqua, Filippo Brighina, N. Rini, G. Puorro, A. Marsili, Matteo Garibaldi, L. Fionda, Francesco Saccà   +12 more
semanticscholar   +1 more source

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

Therapeutic Advances in Neurological Disorders, 2020
Background: In the phase III eculizumab for refractory generalized myasthenia gravis REGAIN study [ClinicalTrials.gov identifier: NCT01997229] and its open-label extension (OLE) [ClinicalTrials.gov identifier: NCT02301624], patients with treatment ...
Saiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa, Richard J. Nowak, Heinz Wiendl, Kenji P. Fujita, Fanny O’Brien, James F. Howard   +7 more
doaj   +1 more source

Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition

American journal of hematology/oncology
Crovalimab is a novel C5 complement inhibitor that enables rapid and sustained C5 inhibition with subcutaneous, low‐volume self‐administration every 4 weeks.
Alexander Röth, Guangsheng He, Hongyan Tong, Zenghua Lin, Xiaoqin Wang, C. Chai-Adisaksopha, Je-Hwan Lee, Andres Brodsky, Chattree Hantaweepant, Teresita E. Dumagay, R. Demichelis-Gómez, P. Rojnuckarin, Jing Sun, Martin Höglund, Junho Jang, A. Gaya, Fernando Silva, N. Obara, Richard J. Kelly, Leigh Beveridge, Simon Buatois, S. Chebon, Brittany Gentile, Pontus Lundberg, S. Sreckovic, Jun-Ichi Nishimura, A. Risitano, Bing Han   +27 more
semanticscholar   +1 more source

Eculizumab hepatotoxicity in pediatric aHUS

Pediatric Nephrology, 2014
Eculizumab is a humanized anti-C5 antibody approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use is increasing in children following reports of its safety and efficacy.We reviewed biochemical and clinical data related to possible drug-induced liver injury in 11 children treated with eculizumab for aHUS in a single center ...
Christoph Licht, Christoph Licht, Janusz Feber, Simon C. Ling, Simon C. Ling, Sibylle Tschumi, Wesley Hayes, Michael Kirschfink   +7 more
openaire   +3 more sources

Eculizumab in kidney diseases

Journal of Nephropharmacology, 2023
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucidated.
Fatemeh Pour-Reza-Gholi, Sara Assadiasl
openaire   +2 more sources

Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland [PDF]

, 2017
Factor H autoantibodies can impair complement regulation, resulting in atypical hemolytic uremic syndrome, predominantly in childhood. There are no trials investigating treatment, and clinical practice is only informed by retrospective cohort ...
Almond, M, Awan, A, Booth, C, Brocklebank, V, Finlay, E, Fitzpatrick, M, Gilbert, RD, Goodship, TH, Hegde, S, Inward, C, Johnson, S, Kaur, A, Kavanagh, D, Kerecuk, L, Kinoshita, M, Marchbank, KJ, Marks, SD, Salama, AD, Sheerin, NS, Sheerin, TP, Tyerman, K, Walsh, PR, Webb, N, Wong, EKS   +23 more
core   +1 more source

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.

Blood, 2019
Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate, complete, and sustained C5 inhibition. This phase 3, open-label study assessed the noninferiority of ravulizumab to eculizumab in complement inhibitor-naive adults with paroxysmal
J. W. Lee, F. Sicre de Fontbrune, Lily Wong Lee Lee, V. Pessoa, S. Gualandro, W. Füreder, V. Ptushkin, S. Rottinghaus, L. Volles, L. Shafner, R. Aguzzi, R. Pradhan, H. Schrezenmeier, A. Hill   +13 more
semanticscholar   +1 more source